Posttransplant lymphoproliferative disorders occurring under primary FK 506 immunosuppression.

P OSlTRANSPLANT Iymphoproliferative disease (PTLD) is a well-recognized complication of immunosuppression.I Previous reports of patients immunosuppressed with cyclosporine (eyA) revealed a 1.7% incidence of PTLD in solid-organ transplant recipients and a strong association with the Epstein-Barr virus «EBV).~ The use of FK 506 in clinical trials has resulted in improved patient and graft survival.as well as a reduction in the prevalence of infectious complications and as a result infection-related mortality ..I•~ PTLD has also been seen among the complications observed in patients treated with FK 506.having a reported incidence of 0.7% to 1.5%.~.fIThis report descnbes the clinical and pathologic features of PTLD arising In the solid-organ transplant recipients treated primarily with FK 506.